Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 8/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 6/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24554201 | 1.00 | CSNK1D (0.40) | CSNK1DCSNK1EMAPK14NR3C2MAPK13 | |
| SCHEMBL29682875 | 0.90 | MAPK14 (0.50) | CSNK1DMAPK14MAPK13MAPK12KCNH2 | |
| SCHEMBL24553783 | 0.90 | MAPK14 (0.50) | CSNK1DMAPK14MAPK13MAPK12KCNH2 | |
| SCHEMBL31680474 | 0.89 | RIPK3 (0.43) | CSNK1DCSNK1EMAPK14NR3C2MAPK13 | |
| SCHEMBL29683274 | 0.88 | NR3C2 (0.44) | CSNK1DCSNK1EMAPK14NR3C2MAPK13 | |
| SCHEMBL24554150 | 0.88 | NR3C2 (0.44) | CSNK1DCSNK1EMAPK14NR3C2MAPK13 | |
| SCHEMBL24554168 | 0.85 | KCNK3 (0.38) | CSNK1DCSNK1EMAPK14KCNK3 | |
| SCHEMBL24554136 | 0.82 | KCNK3 (0.42) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL24554360 | 0.82 | CSNK1D (0.45) | CSNK1DCSNK1EMAPK14GSK3B | |
| SCHEMBL29683049 | 0.82 | CSNK1D (0.45) | CSNK1DCSNK1EMAPK14GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| WO-2022127756-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | PACSIN2, CSNK1A1, CSNK1G3 | CSNK1D 12/4885CSNK1E 4/4885MAPK14 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.